Become a Member | Print Page | Contact Us | Report Abuse | Sign In
Thyroid Cancer Clinical Trials
Share |


 

Clinical Trials.gov  Identifier (Click for more information)      ITOG Clinical  Trials     
 NCT03914300   Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated  Thyroid Cancer    
 
 
   
 NCT02973997   Combination Immunotherapy with Multikinase Inhibitor (MKI) in Progressive, Radiodine-resistant Differentiated  Thyroid Cancers    

 
   
 NCT02393690   Iodine I-131 With or Without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer    

 
   
 NCT03157128   Phase 1/2 Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and  Medullary Thyroid Cancer
   

 
   
 NCT02143726   Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer
   

 
   
 NCT02657369   An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)    

 
   
NCT01811212   Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
   

 
   
  

 NIH- National Cancer Institue 

Treatment Clinical Trials for Thyroid Cancer

  
     
 NCT02465060  Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)  
 NCT02834013  Nivolumab and Ipilimumab in Treating Patients with Rare Tumors  
 NCT03170960  Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors  
   A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy  
   Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors  
   Phase 1 / 2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors  
   Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations  
   Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer  
   Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158 / KEYNOTE-158)  
   Lenvatinib and pembrolizumab in DTC  
   Stereotactic or Hypofractionated Radiation Therapy in Treating Patients with Recurrent or Metastatic Head and Neck Cancer  
   Study of Cemiplimab Combined with Dabrafenib and Trametinib in People with Anaplastic Thyroid Cancer  
   Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced / Metastatic Solid Tumors  
     
     
Connect With Us

International Thyroid Oncology Group

5166 Commercial Drive

Yorkville, New York 13495

614-293-9779

Our mission
To catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.